Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of LTP001 in pulmonary arterial hypertension
2022-002007-38Phase 2Active
- Sponsor
- Novartis
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LTP001 in pulmonary arterial hypertension (PAH), sponsored by Novartis. Primary endpoint: Safety outcomes. Started Dec 2022; status: active.
02
Drugs
LTP001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2022-002007-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002007-38.